|
|
| Future-Proof Your Process | Mobius® iFlex Bioreactors for upstream processes are a scalable portfolio of stirred tank bioreactors that leverage single-use bags with enhanced strength, made with our innovative Ultimus® film. Perfusion applications are supported with ease by integrating a perfusion tower, that uses the Cellicon® Filter Assemblies to retain cells in the bioreactor vessel while removing spent media. Future-proof your process with modular flexibility, and request a demo or technical consultation with our experts today! |
|
|
FOCUS ON UPSTREAM MANUFACTURING |
|
|
|
By Bioprocess Online Live | In this segment of the Bioprocess Online Live event Process Optimization or Full-Scale Automation, David Bruehlmann, Ph.D. addresses how required tech investment, validation times, and staff training impact the return on continuous investment. We also analyze the results of an audience poll on process intensification adoption and discuss energy and perfusion media consumption in continuous versus batch processing. | |
|
|
|
| Simpler, Faster, Cheaper Advanced Therapy Manufacturing | Application Note | Repligen | Discover how TFDF-based perfusion technology boosts lentiviral vector production by over 10-fold, slashes costs, and accelerates the commercialization of CAR-T and other advanced cell therapies. |
|
|
|
|
| High-Titer rAAV Production In Bioreactors Using Producer Cell Lines | Poster | By J. Coronel, A. Al-Dali, A. Patil, K. Srinivasan, T. Braß, K. Hein, and S. Wissing, Cytiva | Here, we detail the upstream process development and optimization for an AAV8-GFP proof-of-concept (PoC) producer single cell clone (SCC) in both batch and perfusion modes. |
|
|
| Utilizing Fed-Batch Intensification To Increase Titer | Article | By Ruth Rowland-Jones, Lonza | Learn how the advanced principles of process intensification can be applied to process and equipment design, increasing facility throughput, and ultimately offering a wide range of benefits to customers. |
|
|
|
|
| Webinar: CAR-T Innovation: Balancing Allogeneic & Autologous Cell Therapy | Join us for an insightful webinar addressing critical CAR-T manufacturer pain points and explore strategies to achieve balanced development of allogeneic (off-the-shelf) and autologous (patient-specific) treatments by 2030. Hear how utilizing technology, adaptive regulatory pathways, supply chain and logistics networks, clinical integration, research, and collaboration can improve patient outcomes and advance cell therapy. |
|
|
UPSTREAM MANUFACTURING SOLUTIONS |
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
